Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimta Beats Gemcitabine In Some NSCLC Types

This article was originally published in The Pink Sheet Daily

Executive Summary

But Phase III results show similar efficacy in patients overall.

You may also be interested in...



ASCO Preview Highlights Study Of Alimta For First-Line NSCLC

Maintenance therapy with Lilly’s pemetrexed shows increase in progression-free survival in the only drug-related abstract in ASCO’s press call.

Lilly Aims To Have 30 NMEs In Clinic By 2009

Goal is to launch an average of two products per year by 2011 and three a year starting in 2014, CEO Taurel says.

Lilly Alimta To Be Available In Two Weeks Following Five-Month Review

Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS067820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel